M.S.D. LIMITED

To discuss rare disease policy development in Ireland and to advocate for increased attention on the the rare disease health policy area in the Oireachtas.

To highlight to Irish MEPs, MSD Ireland’s key EU health policy priorities in advance of the European Elections in May 2024 including Better Health for All Europeans, Creating Jobs that Matter, Supporting Innovation and Encouraging Sustainability. ::To highlight to Irish MEPs,…

To raise industry wide concerns in Ireland regarding the impact of some aspects of the EU Commission’s proposals to revise the general pharmaceutical legislation, on IP protection.::To discuss the Irish Government's position of support, at present, for the Commissions proposals…

To highlight to the new Minister of Finance MSD Ireland’s key health policy areas including reform of the EU pharmaceutical legislation (GPL) and reform of the reimbursement system so as to prevent the current delays for patients in Ireland accessing new medicines.

To discuss health policy matters such the Irish position on the EU's General Pharmaceutical Legislation revision, the Department of Health's Mazars Report implementation and Ireland's reimbursement system and the need for a national plan for the eradication of HPV in Ireland to…

That Government continues to recognise the strategic importance of the pharmaceutical industry and continues to be a strong policy advocate not simply to finesse or avoid a cut in Regulatory Data Protection, but to strengthen inter-related IP supports for medicines in Europe as…

To highlight the importance for Ireland and for Europe to continue to be viewed as a welcoming environment in policy terms for ongoing investment by the pharmaceutical industry in the light of the EU pharmaceutical legislation revision and to advocate for increased funding for…

To discuss with Irish EU policy stakeholders and public representatives, the MSD Ireland position on the revision of the EU Pharmaceutical legislation and our hopes that Ireland will continue with its supportive position and work with the Commission, other Member States and MEPs…

To discuss with Irish policy stakeholders, MSD Ireland’s position on the Revision of the EU Pharmaceutical Legislation and MSD hopes that the Irish Government and its representatives in Europe will continue with its supportive position and work with the Commission, other Member…

To update the Deputy on MSD Ireland's economic impact, to highlight problems with the policy for the reimbursement process in Ireland and to discuss elements of the new rare disease plan.

to seek an update on the Government's policy direction surrounding the appointment of new staffing resources to the reimbursement process in 2024.

to secure a better understanding of the impact of Varicella on Irish hospitals in 2023 and to understand the Irish Government's policy on Varicella

That dedicated funding be allocated for the continued reimbursement of new medicines in Budget 2024.

For government to reassesses its decision not to allocate dedicated funding for new medicines in Budget 2024 and to seek commitments on generating a dedicated funding package which will allow for a continued and uninterrupted flow of new medicines.

To highlight problems in Ireland faced by patients with TNBC and to outline key areas of difficulties as experienced by people working in the field and to highlight the areas in urgent need of attention.